促甲状腺激素释放激素刺激促甲状腺激素试验在100例抑郁症患者中的诊断和治疗价值

Diagnostic and therapeutic value of testing stimulation of thyroid-stimulating hormone by thyrotropin-releasing hormone in 100 depressed patients.

作者信息

Vanelle J M, Poirier M F, Benkelfat C, Galinowski A, Sechter D, Suzini de Luca H, Lôo H

机构信息

Department of Mental Health and Therapeutics, Sainte-Anne Hospital, Paris-Cochin University Clinic, France.

出版信息

Acta Psychiatr Scand. 1990 Feb;81(2):156-61. doi: 10.1111/j.1600-0447.1990.tb06471.x.

DOI:10.1111/j.1600-0447.1990.tb06471.x

PMID:2109497

Abstract

The thyrotropin-releasing hormone (TRH) test was performed in 100 depressed patients, including 73 patients with a major depressive episode (MDE) according to DSM-III. Thirty-one patients subsequently received an antidepressant with a predominant serotoninergic action (indalpine or citalopram), and 27 patients received a noradrenergic antidepressant (maprotiline). The diagnostic value of the TRH test was not conclusive for any of the subgroups of depressed patients: MDE, MDE with melancholia or MDE in bipolar patients. Similarly, the value of the TRH test in the choice of antidepressant treatment according to the monoaminergic action was not convincing. These results are discussed in the light of the data of the international literature.

摘要

对100名抑郁症患者进行了促甲状腺激素释放激素（TRH）测试，其中包括73名根据《精神疾病诊断与统计手册》第三版（DSM-III）诊断为重度抑郁发作（MDE）的患者。31名患者随后接受了主要具有5-羟色胺能作用的抗抑郁药（吲哚平或西酞普兰），27名患者接受了去甲肾上腺素能抗抑郁药（马普替林）。TRH测试对任何抑郁症患者亚组（MDE、伴有抑郁发作的MDE或双相情感障碍患者中的MDE）的诊断价值都不明确。同样，根据单胺能作用，TRH测试在选择抗抑郁治疗方面的价值也不令人信服。结合国际文献数据对这些结果进行了讨论。